Sarepta Therapeutics | SRPT - Debt



Sarepta Therapeutics reported $1.14B in Debt for its fiscal quarter ending in March of 2025.

Debt Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 48.76M 48.76M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amgen USD 57.38B 2.72B Mar/2025
Biogen USD 6.59B 296.8M Jun/2025
BioMarin Pharmaceutical USD 595.65M 585K Mar/2025
Daiichi Sankyo JPY 101.33B 97M Mar/2025
Eli Lilly USD 38.52B 4.87B Mar/2025
Gilead Sciences USD 24.95B 1.76B Mar/2025
Incyte USD 42.41M 5.29M Jun/2025
Insmed USD 564.1M 567.29M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Pfizer USD 62.11B 2.24B Mar/2025
PTC Therapeutics USD 2.4B 17.29M Mar/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Roche Holding CHF 34.44B 5.23B Jun/2024
Sanofi 22.28B 1.24B Jun/2025
Sarepta Therapeutics USD 1.14B 1.16M Mar/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 38.27M 38.27M Mar/2025
Vertex Pharmaceuticals USD 1.65B 1.54B Mar/2025